Analysis
PublicINSTITUTE FOR CANCER RESEARCH, THE holds $2.7M across 7 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Jul 30, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.
Contract facts
FederalNo full NAICS 541711 intel page yet. Browse NAICS intelligence
TASK ORDER AWARD "NOVEL NON-COX INHIBITORY SULINDAC DERIVATIVE FOR COLORECTAL CANCER CHEMOPREVENTION WITH SELECTIVE PDE-10 AND WNT/B-CATENIN INHIBITORY ACTIVITY
Recompete timing
PublicCurrent PoP ended Jul 30, 2026 (18 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Watch this contract — one email →Incumbent footprint
Public recordINSTITUTE FOR CANCER RESEARCH, THE — $2.7M obligated across 7 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Track this contract
Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open INSTITUTE FOR CANCER RESEARCH, THE’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Frequently asked questions
What is contract 75N91018F00003?
75N91018F00003 (TASK ORDER AWARD "NOVEL NON-COX INHIBITORY SULINDAC DERIVATIVE FOR COLORECTAL CANCER CHEMOPREVENTION WITH SELECTIVE PDE…) is a Department of Health and Human Services (HHS) award with an estimated value of $32.8M, currently held by INSTITUTE FOR CANCER RESEARCH, THE. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.
Who is the incumbent on 75N91018F00003?
INSTITUTE FOR CANCER RESEARCH, THE is the incumbent with $2.7M across 7 related awards in SCOUT’s public footprint. The current period of performance ends Jul 30, 2026.
When does 75N91018F00003 come up for recompete?
SCOUT tracks a period-of-performance end of Jul 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →